Pancreatic cancer is a highly lethal malignancy with few effective therapies. We performed exome sequencing and copy number analysis to define genomic aberrations in a prospectively accrued clinical cohort (n 5 142) of early (stage I and II) sporadic pancreatic ductal adenocarcinoma. Detailed analysis of 99 informative tumours identified substantial heterogeneity with 2,016 non-silent mutations and 1,628 copy-number variations. We define 16 significantly mutated genes, reaffirming known mutations (KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1), and uncover novel mutated genes including additional genes involved in chromatin modification (EPC1 and ARID2), DNA damage repair (ATM) and other mechanisms (ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6). Integrative analysis with in vitro functional data and animal models provided supportive evidence for potential roles for these genetic aberrations in carcinogenesis. Pathway-based analysis of recurrently mutated genes recapitulated clustering in core signalling pathways in pancreatic ductal adenocarcinoma, and identified new mutated genes in each pathway. We also identified frequent and diverse somatic aberrations in genes described traditionally as embryonic regulators of axon guidance, particularly SLIT/ROBO signalling, which was also evident in murine Sleeping Beauty transposon-mediated somatic mutagenesis models of pancreatic cancer, providing further supportive evidence for the potential involvement of axon guidance genes in pancreatic carcinogenesis.
Pancreatic cancer is the fourth leading cause of cancer death, with an overall 5-year survival rate of ,5%, statistics that have not changed in almost 50 years 1 . Advances in neoadjuvant and adjuvant chemotherapeutic regimens have resulted in some improvement in outcome, but pancreatectomy remains the single most effective treatment modality for pancreatic cancer, and offers the only potential for cure. Only 20% of patients present with localized, non-metastatic disease which is suitable for resection 2 . Those who undergo resection and receive adjuvant therapy have a median survival of 12-22 months and a 5-year survival of 20-25% 3 . Existing systemic therapies are only modestly effective and the median survival for patients with metastatic disease remains 6 months. Genomic characterization of pancreatic ductal adenocarcinoma (PDAC), which accounts for over 90% of pancreatic cancer, has so far focused on targeted polymerase chain reaction (PCR)-based exome sequencing of primary and metastatic lesions propagated as xenografts or cell lines 4 . A deeper understanding of the underlying molecular pathophysiology of the clinical disease is needed to advance the development of effective therapeutic and early detection strategies.
Clinical cohort
A cohort of 142 consecutive patients with primary operable, untreated PDAC who underwent pancreatectomy with curative intent (preoperative clinical stages I and II) were recruited, and consent was obtained for genomic sequencing through the Australian Pancreatic Cancer Genome Initiative (APGI), the Baylor College of Medicine Pancreatic Cancer Genome Project and the Ontario Institute for Cancer Research Pancreatic Cancer Genome Study (ABO collaboration) between June 2005 and June 2011 as part of the International Cancer Genome Consortium (ICGC) 5 . Detailed clinico-pathological characteristics of the cohort demonstrated features typical of resected PDAC with regard to tumour size, grade, lymph node metastasis and survival when compared to multiple retrospectively acquired cohorts [6] [7] [8] , defining the accrued population as representative of the clinical disease in the community (Supplementary Table 1 and Supplementary Fig. 1 ).
Cellularity and mutation detection
A major challenge in genomic sequencing is the low malignant epithelial cell content of many cancers, which can adversely impact on the sensitivity of mutation detection. Most sequencing studies so far have used samples with .70% tumour cellularity, or cell lines/xenografts 4, 9 .
To implement genomic sequencing approaches in clinical practice, it is imperative to efficiently and accurately detect actionable mutations in diagnostic clinical samples. We devised methodologies to overcome the challenges associated with extensive desmoplastic stroma that is characteristic of the majority of PDAC, and these strategies facilitated the discovery of novel molecular mechanisms in the pathophysiology of this disease. The cellularity of each primary sample was estimated through pathological review, deep amplicon-based sequencing of exons 2 and 3 of KRAS (average depth of 1,0003), and single nucleotide polymorphism (SNP) array-based cellularity estimates using a novel algorithm (qpure) 10 . KRAS mutations were identified in 93% of 142 cases and tumour cellularity ranged from 5% to 85% with a mean of 38% (Supplementary Table 2 , Supplementary Figs 2 and 3 , and Supplementary Methods).
To inform cellularity thresholds for subsequent analyses, we defined the impact of stromal DNA content on mutation detection by exome capturing and sequencing different mixtures of cancer cell line and matched germline DNA (100%, 80%, 60%, 40%, 20% and 10% cell line DNA) when sequenced to a depth of 703 coverage. Using these data as a standard, the median sensitivity to detect true positives across all samples in the cohort with greater than 20% epithelial cellularity was estimated at 45% (Supplementary Table 3 ). An informative cohort of 99 patients who had greater than 20% cellularity and/or $10 validated somatic mutations was taken forward for further analysis.
Mutation detection and CNV analysis
We performed hybrid-selection-based capture and sequencing of the entire exomes of tumour and matched normal DNA derived from all 142 patients using a combination of capture systems and nextgeneration sequencing platforms (see Supplementary Methods). The sequence depths at each site (APGI 653, BCM 1043 and OICR 2053) were adopted to ensure suitable sensitivity across their respective cohorts (Supplementary Table 3 ). In the informative 99 samples, we detected 2,627 high-confidence mutations, 2,016 of which were nonsilent (Table 1) . A total of 1,502 of these events (1,350 non-silent) were independently validated via an orthogonal sequencing method (see Supplementary Methods). The average number of mutations detected per patient was 26 (range 1-116), consistent with the expected sensitivity based on cellularity estimates and previous studies 4, 11 (Supplementary Table 2 ). We confirmed the high prevalence of genetic aberrations known to be important in PDAC and observed mutations in 38 of the 79 genes (48% overlap) that occurred more than once previously reported by ref. 4 , and 186 of all 998 mutated genes (19% overlap) in that study. We also defined a large number of novel mutations (1,456 genes), most of which occurred at low frequency (see Supplementary Tables 4-6 and Supplementary Fig. 4 for detailed comparisons). The observed transversion/transition rates in the cohort correlated closely with those previously reported in PDAC cell lines and xenografts (Supplementary Table 7) .
Significant mutated gene analysis 12 of genes with non-silent mutations that occurred in 2 or more individual cancers identified 16 genes in the top 20 mutated genes in 2 of 3 stringent analytical approaches ( Table 2, Supplementary Table 8 and Supplementary Methods) and reaffirmed the importance of mutations known to occur in PDAC: KRAS, TP53, CDKN2A, SMAD4, MLL3, TGFBR2, ARID1A and SF3B1. Novel significantly mutated genes included additional genes involved in chromatin modification (EPC1 and ARID2) and ATM, recently implicated as a PDAC susceptibility gene through bi-allelic inactivation in a case of familial PDAC (germline mutation and loss of heterozygosity (LOH) in the tumour) 13 . Aberrations of ATM occurred in 8% of our cohort (mutated in 5%, LOH or loss in 5%, with two patients exhibiting both mutation and LOH or loss) and mutations detected in other genes not previously reported: ZIM2, MAP2K4, NALCN, SLC16A4 and MAGEA6 (Table 2 ). GISTIC2.0 14 identified 30 genes affected by copy-number alterations (Q value ,0.0001) and included losses of CDKN2A and SMAD4 (Supplementary Table 4 ).
Pathways in pancreatic cancer
To better understand potential underlying mechanisms of importance in PDAC, we performed a series of pathway analyses using genes that were recurrently mutated in two or more individuals using GeneGO 15 , and identified mechanisms known to be important in cancer: G1/S checkpoint machinery (P 5 1.49 3 10 Table 9 ). The inclusion of mutation data for 24 cases from ref. 4 strengthened the association of axon guidance (P 5 3.3 3 10
27
), and was more evident still when all mutated genes in our data set were used as input (P 5 4.67 3 10
28
).
Functional relevance of genomic events
Differentiating somatic driving events of carcinogenesis from passenger mutations is a major challenge in cancer genomics 16 . Despite significant advances in computational algorithms, experimental evidence of functional relevance is paramount. We used data from three published experimental biological screens to infer functional consequences for the individual genomic events and the pathways we identified. These included data from two independent Sleeping Beauty transposon (SB) mutagenesis screens in Kras transgenic mouse models of PDAC 17, 18 and an in vitro short hairpin RNA (shRNA) screen which examined the consequences of downregulating 11,194 putative cancer genes on survival in a panel of 102 cell lines (13 pancreatic) 19 (Supplementary Methods and Supplementary Figs 5 and 6 ). Data from these screens confirmed the functional importance of KRAS, TP53, CDKN2A and SMAD4 mutations and attributed potential functional relevance to most significantly mutated genes-MLL3, TGFBR2, SF3B1, EPC1, ARID1A, ARID2, MAP2K4, ATM, NALCN, ZIM2, SLC16A4 (Table 2 )-and many genes mutated at low frequency (Supplementary Table 4 ).
Pathway analysis of high confidence insertions in SB transposon mutagenesis screens demonstrated enrichment for axon guidance genes (P 5 1.6 3 10 23 ), providing independent supportive evidence for a potential role in the pathogenesis of PDAC. In these screens, 14 genes involved in axon guidance pathways were detected (5 genes common to both). In addition, a further 32 genes were mutated in at least one SB pancreatic tumour (out of 21) but did not meet the significance threshold with the stringent analyses that were applied 17 (Supplementary Tables 10 and 11) .
Axon guidance pathway genes
The class of genes traditionally described for their roles in axon guidance (semaphorins, slits, netrins and ephrins) are important regulators of ; however, the incidence of aberrations in these genes in cancer is largely unknown. We identified recurrent mutations and copy-number variations (CNVs) of axon guidance pathway genes in this cohort ( Fig. 1 and Supplementary Table 4 ): SLIT2 and ROBO2 mutations were present in 5% of patients, with focal copy-number losses of ROBO1, and SLIT2 detected by GISTIC2.0 analysis and confirmed by manual review, potentially having an impact on a further 15% of the cohort, suggesting that aberrant SLIT/ROBO signalling is potentially a common feature of PDAC (Figs 1 and 2 ). In addition, we used targeted PCR-based sequencing of an additional 30 cases of PDAC for axon guidance genes and identified mutations in ROBO1 in two patients and additional mutations in SLIT2 and ROBO2 (one patient each). Low mRNA expression of the ROBO2 receptor was associated with poor patient survival (P 5 0.04). Furthermore, high mRNA expression of ROBO3, a known inhibitor of ROBO2 signalling 21 , demonstrated an appropriate reciprocal inverse association with poor survival (P , 0.006) (Fig. 2) .
Class 3 semaphorins (SEMA3A and SEMA3E) exhibited significant amplification in 18% of patients and an additional 3% harboured mutations (Fig. 1) . Semaphorins signal through neuropilin and plexin receptors to elicit their effects 22 . SEMA3A amplification correlated with high mRNA expression on microarray (P 5 0.03), and high mRNA expression of SEMA3A and PLXNA1, another molecule central to semaphorin signalling, were both associated with poor patient survival on univariate analysis (Fig. 3a) , and were independently prognostic on multivariate analyses with clinico-pathological variables (Supplementary Table 12 ).
To elucidate further the significance of the observed CNV events, we reviewed copy number, CNV segment size and changes in heterozygosity of axon guidance genes in a recent independent CNV analysis of 39 fine-needle aspiration biopsies 23 and the 16 PDAC cell lines in the CONAN database (http://www.sanger.ac.uk/cosmic) 24 . Overall, the predominant changes recapitulated our studies, showing frequent focal losses within genes involved in SLIT/ROBO signalling, and gains in genes involved in canonical semaphorin signalling (Supplementary  Tables 4, 13 and 14) .
To assess whether dysregulation of axon guidance genes is associated with early neoplastic transformation, as are many developmental signalling pathways, we examined mRNA expression in murine models of early pancreatic carcinogenesis (in vitro acinar-to-ductal metaplasia and in vivo pancreatic injury). Expression levels of components of SLIT/ROBO and semaphorin signalling changed progressively from normal pancreas, through acinar-to-ductal metaplasia and pancreatic injury to genetically engineered murine PDAC, indicating a role for the dysregulation of these axon guidance genes in tumour initiation and progression ( Fig. 3b and Supplementary Table 15 ).
Discussion
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regeneration, wound healing and other basic cellular processes 22, 27 . The widespread genomic aberrations observed here in axon guidance genes suggests that they may have a role in PDAC, joining mounting evidence in other cancers 20, 28 , including a recent report demonstrating ROBO2 mutations in liver-fluke-associated cholangiocarcinoma 29 . In addition, evidence from cancers of the lung, breast, kidney and cervix implicate aberrant SLIT/ROBO signalling in carcinogenesis 20 ; Robo1 knockout mice develop bronchial hyperplasia and focal dysplasia, and inactivation of Slit2 and Slit3 leads to the development of hyperplastic disorganized lesions in the breast 20 . Upregulation of MET and WNT signalling have important roles in PDAC, and recent data indicate that SLIT/ROBO signalling modulates MET and WNT signalling activity through CDC42 and b-catenin, respectively 20 . Loss of SLIT/ ROBO signalling can potentially be an alternative mechanism for deregulating these pathways downstream of their receptors, and in addition could influence the activity of inhibitors that target these upstream components, for example, MET inhibitors (Fig. 2) .
Class 3 semaphorins are the only secreted semaphorins in vertebrates. They regulate cell growth, invasiveness and angiogenesis, and are highly expressed in metastatic cells in many cancer types 30, 31 . Although aberrant semaphorin signalling in cancer seems to be organ specific 32 , our finding that high expression of SEMA3A and its receptor PLXNA1 co-segregates with poor patient survival is supported by a previous study that reported this association and also demonstrated promotion of invasiveness of PDAC cell lines by SEMA3A
31
. Therapeutics targeting molecules involved in axon guidance have been developed as potential strategies to facilitate neuronal regeneration after injury 33 , but are yet to be assessed for their role in cancer treatment. As illustrated here, global genomic analysis of large, well-annotated and clinically homogeneous cohorts of patients can identify mechanisms that are common among genomically diverse cancers, and will be pivotal in the development of novel therapeutic strategies that are guided by the determination of the molecular phenotype of individual patients 34 . Future work will be required to determine which key components, when damaged, drive the disease, and these mechanisms will need to be assessed in molecularly well-characterized preclinical models 35 . The potential therapeutic strategies identified will then require testing in appropriate clinical trials that are specifically designed to target subsets of patients stratified according to well-defined molecular markers 36, 37 .
METHODS SUMMARY
Sample acquisition and processing. Samples used were prospectively acquired and restricted to primary operable, non-pretreated pancreatic ductal adenocarcinoma. Representative sections were reviewed independently by at least one additional pathologist with specific expertise in pancreatic diseases. Samples either had full face frozen sectioning performed in optimal cutting temperature (OCT) medium, or the ends excised and processed in formalin to verify the presence of carcinoma in the sample to be sequenced and to estimate the percentage of malignant epithelial nuclei in the sample relative to stromal nuclei. Macrodissection was performed if required to excise areas that did not contain malignant epithelium. Sequencing. Cellularity of each tumour sample was estimated with pathology review, deep sequencing of KRAS and a method developed using genome-wide SNP array data (qpure 10 ). Exon capture was performed using the SureSelect II or Nimblegen capture methods and paired-end sequenced on the SOLiD (v4) or GAII/HiSeq platforms. Somatic mutations were called and then verified on the Ion Torrent Personal Genome Machine (Life Technologies Corporation) and 454 (Hoffman-La Roche Limited). Analysis. Significantly mutated genes were identified using the Genome MuSiC package 12 . DNA copy number analyses were performed using the Illumina HumanOmni1 Quad genotyping arrays and GenoCN software. Recurrent and significant copy number changes were identified using GISTIC2.0 14 . Functional enrichment of gene categories was assessed using the Metacore package (Thomson-Reuters Corporation) and the MSigDB v3.0 database 38 . All sample information and data for mutation, copy number and expression analyses were submitted to the ICGC DCC at http://dcc.icgc.org/. A complete description of the materials and methods including approvals for human research and animal experimentation is provided in Supplementary Information.
